Product Description
Uridine triacetate (Vistogard) was approved in 2015 for adult and pediatric patients who exhibit early-onset severe or life-threatening 5-FU/capecitabine toxicities or present with an overdose. Uridine triacetate delivers high concentrations of uridine, which competes with toxic 5-FU metabolites. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27622829/)
Mechanisms of Action: Antimetabolite Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Greece | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Wellstat
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Purine-Pyrimidine Metabolism, Inborn Errors
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01432301 |
NCT01432301 | N/A |
Approved for marketing |
Neutropenia |
None |
2019-03-19 |
Treatments |
|
NCT02110147 |
NCT02110147 | P3 |
Completed |
Purine-Pyrimidine Metabolism, Inborn Errors |
2014-12-01 |
2019-03-20 |
Treatments |